Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
about
Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicitySmall molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Rhabdomyolysis due to Trimethoprim-Sulfamethoxazole Administration following a Hematopoietic Stem Cell Transplant.Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.Exploring concepts of in vitro time-dependent CYP inhibition assays.Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015.A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant.Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway.Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q29247916-F52C5481-8BE6-44DA-B52E-1171AF1DD785Q30664269-B9CDC66D-C3B5-4250-B01D-A267A1CAB30FQ35023711-30C25071-E5AB-4DEF-A825-F0943D721BEDQ36236286-581A350A-4C3B-4D79-A4A4-843FDCEF761CQ37320052-D8D5E937-664C-4CDC-9217-C45FF7A9FE06Q37325598-9BAD96CC-C5F5-4B64-9765-DB7EBE8D1431Q38099049-08082B1E-6250-4150-9DC5-5631C6E8DF2FQ38164432-BC6D51CF-3D2A-43E1-8C79-FFFDC3EE0A71Q38268600-E1E64E34-6C68-44BA-84EA-97C36F37D3AEQ38346846-260FB87C-A517-4E18-BA6E-82083F246ED8Q38675826-4E769FF1-27A4-4670-9321-81EB24EAE0B4Q38763312-56E4CF01-2C83-46FC-BF17-1166AF6950D4Q38819541-555315B2-1E95-4B5D-AE15-A272955A778BQ40003126-5B6E2727-0E95-453B-ABE4-4D0205B78161Q41962845-A42BE598-6D52-4B39-8750-48767E0EC828Q42289924-D54A3605-B6B3-4DA8-9568-539AAC9AE9ABQ42544909-F390EAE0-257D-4ED4-BB2D-1A156784FC0BQ44430233-50CF26C4-1982-48C8-8DA0-6EF407F986B8Q46135472-8801610D-07F2-4A1F-B61A-29CC6891D384Q46431899-3C16B4A7-0F14-41A2-BD80-6225A3C736E7Q52334679-0BE5D6C4-5B6B-42F4-9526-7BE59D3A8DB1Q54977664-8518DF7E-5B3D-4216-9F3B-1D519A6BB094Q58788266-72B5BDD0-1EAE-4154-B8D1-EE63B3844614
P2860
Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Drug-drug interaction potentia ...... g-drug interaction prediction.
@en
Drug-drug interaction potentia ...... g-drug interaction prediction.
@nl
type
label
Drug-drug interaction potentia ...... g-drug interaction prediction.
@en
Drug-drug interaction potentia ...... g-drug interaction prediction.
@nl
prefLabel
Drug-drug interaction potentia ...... g-drug interaction prediction.
@en
Drug-drug interaction potentia ...... g-drug interaction prediction.
@nl
P2093
P2860
P1476
Drug-drug interaction potentia ...... g-drug interaction prediction.
@en
P2093
Carol Collins
Chenghong Zhang
Jane R Kenny
S Cyrus Khojasteh
Sophie Mukadam
Suzanne Tay
P2860
P304
P356
10.1007/S11095-012-0724-6
P577
2012-03-14T00:00:00Z